Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.
The company’s stock has a 5-day price change of -0.25% and 7.12% over the past three months. GILD shares are trading -1.48% year to date (YTD), with the 12-month market performance up to 6.57% higher. It has a 12-month low price of $62.07 and touched a high of $98.90 over the same period. GILD has an average intraday trading volume of 6.58 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.89%, -0.84%, and 16.30% respectively.
Institutional ownership of Gilead Sciences, Inc (NASDAQ: GILD) shares accounts for 85.33% of the company’s 1.25B shares outstanding.
It has a market capitalization of $113.41B and a beta (3y monthly) value of 0.20. The stock’s trailing 12-month PE ratio is 1025.93, while the earnings-per-share (ttm) stands at $0.09. The company has a PEG of 109.63 and a Quick Ratio of 1.10 with the debt-to-equity ratio at 1.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.91% over the week and 1.91% over the month.
Analysts forecast that Gilead Sciences, Inc (GILD) will achieve an EPS of 1.7 for the current quarter, 1.78 for the next quarter and 7.56 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.13 while analysts give the company a high EPS estimate of 1.13. Comparatively, EPS for the current quarter was 1.72 a year ago. Earnings per share for the fiscal year are expected to decrease by -34.77%, and 72.54% over the next financial year. EPS should grow at an annualized rate of 9.36% over the next five years, compared to 1.55% over the past 5-year period.
Looking at the support for the GILD, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on January 10, 2025, with the firm’s price target at $87-$113. BofA Securities coverage for the Gilead Sciences, Inc (GILD) stock in a research note released on December 10, 2024 offered a Buy rating with a price target of $109. Wolfe Research was of a view on November 15, 2024 that the stock is Outperform, while Citigroup gave the stock Buy rating on November 14, 2024, issuing a price target of $125. Maxim Group on their part issued Hold rating on November 08, 2024.
